久久视频在线视频精品-日韩亚洲变态另类中文-free性欧美69巨大-mm131巨爆乳美女少妇动态图

Recently, several key aortic intervention products of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec?) have been approved for registration in Ecuador.   This marks Endovastec?’s first entry into the Ecuadorian market, laying a solid foundation for the company's business expansion in the country. The approved products include Castor? Branched Aortic Stent Graft System (Castor?), Talos? Thoracic Stent Graft System(Talos?), Minos? Abdominal Aortic Stent Graft and Delivery System(Minos?), and Hercules? Balloon Inflation Catheter(Hercules?).

Castor? is indicated for the treatment of thoracic aortic dissection involving arch lesions, and is the world’s first stent graft that can simultaneously repair the aorta and supra-arch branch arteries through minimally invasive treatment. The main body of the stent graft and the branch are sutured together, which creatively solves the problem of the introduction and positioning of the unibody branch stent graft, and has the advantages of low postoperative endoleak and high branch patency. The unique unibody design can not only adapt to various arch anatomy, but also reduce surgical trauma and surgical risk. Castor? received marketing approval in China in 2017 and received the certificate of EU custom-made medical device in 2022. It is currently being used in clinical applications in 23 countries worldwide.

Talos? received marketing approval in China in 2022. It is a new-generation of straight tubular thoracic aortic stent graft developed by Endovastec? and the world's first "breathing" stent graft. It is suitable for the surgical treatment of Stanford type B aortic dissection. It can improve the reshaping of the distal true lumen by extending the stent graft length. Its unique distal honeycomb design (length can be selected from 0 mm to 200 mm) can enlarge the distal true lumen diameter of the thoracic aorta, reduce the possibility of spinal cord ischemia caused by overlying intercostal arteries, and improve the long-term treatment effect. 

Minos? is indicated for the endovascular treatment of abdominal aortic aneurysms with proximal aneurysm neck length ≥15 mm. Its delivery sheath outer diameter is only 14F, which significantly reduces the requirements for vascular access during surgery. It offers unique advantages in treating complex abdominal aortic aneurysms, especially those with tortuous necks, short necks, or tortuous and stenotic access arteries. Minos? received marketing approval in China in 2019 and received CE certification in the same year. Currently, it has been introduced into clinical application in 25 countries worldwide, and has garnered widespread recognition and praise from experts across various countries for its excellent clinical performance.

Hercules? Balloon Inflation Catheter   is used to assist expansion of stent grafts after EVAR procedure. It is intended to eliminate type I/III endoleak and reinforce the attachment of the stent graft to the aortic wall by means of fully expanding the stent graft, so as to achieve the better short-term and long-term treatment effects. Hercules? Balloon received marketing approval in China in 2013 and received CE certification in 2016. It is currently being used in clinical application in 8 countries worldwide, with excellent clinical performance.

The approval of these four key aortic products in Ecuador signifies Endovastec?'s further expansion in Latin America, offering a more comprehensive product portfolio in the regional market. This is expected to benefit more local patients suffering from aortic diseases. In the future, Endovastec? is committed to developing and implementing comprehensive medical solutions for aortic, peripheral vascular, and tumor diseases, bringing more high-quality innovative products to the global markets, and creating health benefits for more patients with circulatory diseases worldwide.